Research Article
A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma
Figure 7
Prediction of potential therapeutic compounds as well as assessment of chemosensitivity based on CCP-derived gene signature in TCGA-LIHC cohort. (a) Spearman correlation between CTRP-derived compounds and CCP-derived RS as well as comparison of estimated AUC value between high- and low-risk HCC samples. . (b) Shared mechanisms of action of small molecular compounds derived from CMap database. (c) Comparison of the estimated IC50 value of doxorubicin, cisplatin, gemcitabine, and sorafenib in high- and low-risk HCC samples.
(a) |
(b) |
(c) |